ACADIA Pharmaceuticals Inc. (ACAD) 10-Year Financial Performance & Capital Metrics

ACAD • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.Show more

Revenue $958M +31.8%
EBITDA $247M +463.7%
Net Income $226M +469.5%
EPS (Diluted) 1.36 +467.6%
Gross Margin 91.46% -2.4%
EBITDA Margin 25.75% +375.8%
Operating Margin 24.1% +338.5%
Net Margin 23.64% +380.2%
ROE 38.89% +364.0%
ROIC 45.22% +366.2%
Debt/Equity 0.07 -46.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 16.4% free cash flow margin
✓Strong 5Y sales CAGR of 23.1%
✓Trading near 52-week high

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y145.59%

5Y23.08%

3Y25.54%

TTM12.69%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM103.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM98.72%

ROCE

10Y Avg-40.06%

5Y Avg-17.89%

3Y Avg-7.14%

Latest35.85%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	61K	17.33M	124.9M	223.81M	339.08M	441.75M	484.14M	517.24M	726.44M	957.8M
Revenue Growth %	-0.49%	283.11%	6.21%	0.79%	0.52%	0.3%	0.1%	0.07%	0.4%	0.32%
Cost of Goods Sold+	76.37M	4.41M	13.06M	18.33M	19.6M	20.55M	19.14M	10.17M	45.73M	81.84M
COGS % of Revenue	1251.95%	0.25%	0.1%	0.08%	0.06%	0.05%	0.04%	0.02%	0.06%	0.09%
Gross Profit+	-76.31M	12.93M	111.84M	205.48M	319.48M	421.2M	465M	507.07M	680.71M	875.96M
Gross Margin %	-1250.95%	0.75%	0.9%	0.92%	0.94%	0.95%	0.96%	0.98%	0.94%	0.91%
Gross Profit Growth %	-0.26%	1.17%	7.65%	0.84%	0.55%	0.32%	0.1%	0.09%	0.34%	0.29%
Operating Expenses+	164.67M	285.74M	404.25M	452.92M	566.02M	707.79M	635.44M	730.66M	754.09M	645.16M
OpEx % of Revenue	2699.56%	16.49%	3.24%	2.02%	1.67%	1.6%	1.31%	1.41%	1.04%	0.67%
Selling, General & Admin	90.8M	186.46M	255.06M	265.76M	325.64M	388.66M	396.03M	369.09M	402.47M	488.43M
SG&A % of Revenue	1488.59%	10.76%	2.04%	1.19%	0.96%	0.88%	0.82%	0.71%	0.55%	0.51%
Research & Development	73.87M	99.28M	149.19M	187.16M	240.38M	319.13M	239.41M	361.57M	351.62M	303.25M
R&D % of Revenue	1210.97%	5.73%	1.19%	0.84%	0.71%	0.72%	0.49%	0.7%	0.48%	0.32%
Other Operating Expenses	2.5M	1.33M	3.98M	-1.84M	0	0	0	0	0	-146.51M
Operating Income+	-164.61M	-272.81M	-292.41M	-247.44M	-246.54M	-286.59M	-170.44M	-223.6M	-73.38M	230.79M
Operating Margin %	-2698.56%	-15.74%	-2.34%	-1.11%	-0.73%	-0.65%	-0.35%	-0.43%	-0.1%	0.24%
Operating Income Growth %	-0.77%	-0.66%	-0.07%	0.15%	0%	-0.16%	0.41%	-0.31%	0.67%	4.15%
EBITDA+	-163.97M	-270.99M	-289.7M	-244.44M	-243.78M	-283.65M	-167.09M	-221.57M	-67.83M	246.68M
EBITDA Margin %	-2687.95%	-15.64%	-2.32%	-1.09%	-0.72%	-0.64%	-0.35%	-0.43%	-0.09%	0.26%
EBITDA Growth %	-0.76%	-0.65%	-0.07%	0.16%	0%	-0.16%	0.41%	-0.33%	0.69%	4.64%
D&A (Non-Cash Add-back)	647K	1.83M	2.71M	3M	2.77M	2.93M	3.34M	2.03M	5.55M	15.88M
EBIT	-164.61M	-272.81M	-292.41M	-247.44M	-246.54M	-286.59M	-170.44M	-223.6M	-73.38M	84.28M
Net Interest Income+	499K	2.76M	4.13M	5.35M	11.16M	6.61M	591K	6.61M	17.23M	25.46M
Interest Income	499K	2.76M	4.13M	5.35M	11.16M	6.61M	591K	6.61M	17.23M	25.46M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	499K	2.76M	4.13M	3.51M	12.16M	5.61M	2.92M	10.15M	22.34M	27.28M
Pretax Income+	-164.11M	-270.05M	-288.28M	-243.94M	-234.38M	-280.97M	-167.52M	-213.44M	-51.04M	258.07M
Pretax Margin %	-2690.38%	-15.58%	-2.31%	-1.09%	-0.69%	-0.64%	-0.35%	-0.41%	-0.07%	0.27%
Income Tax+	330K	1.34M	1.12M	1.26M	876K	611K	351K	2.53M	10.25M	31.62M
Effective Tax Rate %	1%	1%	1%	1.01%	1%	1%	1%	1.01%	1.2%	0.88%
Net Income+	-164.44M	-271.39M	-289.4M	-245.19M	-235.26M	-281.58M	-167.87M	-215.97M	-61.29M	226.45M
Net Margin %	-2695.79%	-15.66%	-2.32%	-1.1%	-0.69%	-0.64%	-0.35%	-0.42%	-0.08%	0.24%
Net Income Growth %	-0.78%	-0.65%	-0.07%	0.15%	0.04%	-0.2%	0.4%	-0.29%	0.72%	4.69%
Net Income (Continuing)	-164.44M	-271.39M	-289.4M	-245.19M	-235.26M	-281.58M	-167.87M	-215.97M	-61.29M	226.45M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.63	-2.34	-2.36	-1.94	-1.60	-1.79	-1.05	-1.34	-0.37	1.36
EPS Growth %	-0.72%	-0.44%	-0.01%	0.18%	0.18%	-0.12%	0.41%	-0.28%	0.72%	4.68%
EPS (Basic)	-1.63	-2.34	-2.36	-1.94	-1.60	-1.79	-1.05	-1.34	-0.37	1.37
Diluted Shares Outstanding	100.63M	115.86M	122.6M	126.58M	147.2M	157.33M	160.49M	161.68M	163.82M	166.36M
Basic Shares Outstanding	100.63M	115.86M	122.6M	126.58M	147.2M	157.33M	160.49M	161.68M	163.82M	165.72M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	218.99M	547.9M	373.48M	526.11M	760.25M	717.62M	617.82M	507.94M	616.13M	938.32M
Cash & Short-Term Investments	215.13M	529.04M	341.34M	473.52M	697.43M	631.96M	520.71M	416.82M	438.87M	755.99M
Cash Only	102.14M	163.62M	69.42M	134.76M	189.68M	326.03M	147.44M	114.85M	188.66M	319.59M
Short-Term Investments	112.99M	365.42M	271.92M	338.76M	507.75M	305.93M	373.27M	301.98M	250.21M	436.4M
Accounts Receivable	1.64M	7.14M	18.43M	27.79M	37.87M	50.28M	65.34M	63.08M	102.35M	104.69M
Days Sales Outstanding	9.8K	150.37	53.86	45.32	40.77	41.55	49.26	44.51	51.43	39.9
Inventory	0	4.17M	5.25M	4.07M	6.34M	9.68M	7.88M	6.64M	35.82M	21.95M
Days Inventory Outstanding	-	345.86	146.67	81.04	118.1	171.97	150.28	238.26	285.89	97.89
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	2.91M	13.26M	11.03M	14.1M	22.93M	65M	82.3M	79.88M	132.83M	249.44M
Property, Plant & Equipment	2.2M	3.08M	2.66M	3.31M	12.7M	56.44M	66.31M	61.59M	56.47M	50.79M
Fixed Asset Turnover	0.03x	5.63x	46.92x	67.64x	26.69x	7.83x	7.30x	8.40x	12.86x	18.86x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	7.01M	5.54M	4.06M	2.58M	1.11M	0	0	65.49M	119.78M
Long-Term Investments	375K	2.38M	2.48M	4.83M	7.09M	7.07M	0	12.97M	5.77M	0
Other Non-Current Assets	329K	3.16M	2.83M	6.72M	557K	378K	15.98M	5.31M	5.1M	78.87M
Total Assets+	221.9M	561.15M	384.51M	540.2M	783.18M	782.62M	700.12M	587.81M	748.96M	1.19B
Asset Turnover	0.00x	0.03x	0.32x	0.41x	0.43x	0.56x	0.69x	0.88x	0.97x	0.81x
Asset Growth %	-0.32%	1.53%	-0.31%	0.4%	0.45%	-0%	-0.11%	-0.16%	0.27%	0.59%
Total Current Liabilities+	21.9M	42.59M	49.03M	59.56M	74.83M	105.97M	96.07M	125.63M	254.25M	394.87M
Accounts Payable	1.67M	3.91M	8.79M	3.17M	7.22M	8.49M	6.88M	12.75M	17.54M	16.19M
Days Payables Outstanding	7.99	324.08	245.55	63.06	134.51	150.85	131.12	457.63	140.02	72.21
Short-Term Debt	0	0	0	0	3.43M	5.09M	0	0	9.4M	0
Deferred Revenue (Current)	0	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	14.51M	21.65M	21.39M	33.52M	31.76M	52.46M	25.9M	49.51M	92.31M	36.55M
Current Ratio	10.00x	12.87x	7.62x	8.83x	10.16x	6.77x	6.43x	4.04x	2.42x	2.38x
Quick Ratio	10.00x	12.77x	7.51x	8.76x	10.08x	6.68x	6.35x	3.99x	2.28x	2.32x
Cash Conversion Cycle	-	172.16	-45.02	63.3	24.36	62.66	68.43	-174.86	197.3	65.57
Total Non-Current Liabilities+	232K	157K	191K	1.56M	9.22M	49.64M	63.16M	61.77M	62.95M	60.09M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	6.36M	44.46M	56.13M	52.7M	47.8M	42.04M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	232K	157K	191K	1.56M	2.86M	5.18M	7.03M	9.07M	15.15M	18.06M
Total Liabilities	22.13M	42.74M	49.22M	61.12M	84.05M	155.61M	159.23M	187.4M	317.2M	454.96M
Total Debt+	0	0	0	0	9.79M	49.55M	64.43M	62M	57.2M	51.99M
Net Debt	-102.14M	-163.62M	-69.42M	-134.76M	-179.88M	-276.48M	-83M	-52.85M	-131.45M	-267.59M
Debt / Equity	-	-	-	-	0.01x	0.08x	0.12x	0.15x	0.13x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.21x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-1.08x
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	199.76M	518.41M	335.29M	479.08M	699.13M	627.01M	540.89M	400.41M	431.75M	732.79M
Equity Growth %	-0.35%	1.6%	-0.35%	0.43%	0.46%	-0.1%	-0.14%	-0.26%	0.08%	0.7%
Book Value per Share	1.99	4.47	2.73	3.78	4.75	3.99	3.37	2.48	2.64	4.40
Total Shareholders' Equity	199.76M	518.41M	335.29M	479.08M	699.13M	627.01M	540.89M	400.41M	431.75M	732.79M
Common Stock	10K	12K	12K	14K	15K	16K	16K	16K	16K	16K
Retained Earnings	-662.59M	-933.98M	-1.22B	-1.47B	-1.7B	-1.99B	-2.15B	-2.37B	-2.43B	-2.2B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	11K	106K	-399K	-372K	297K	36K	-192K	-975K	24K	292K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-121.8M	-210.41M	-217.86M	-167.47M	-151.13M	-136.17M	-125.66M	-114.03M	16.7M	157.72M
Operating CF Margin %	-1996.64%	-12.14%	-1.74%	-0.75%	-0.45%	-0.31%	-0.26%	-0.22%	0.02%	0.16%
Operating CF Growth %	-0.83%	-0.73%	-0.04%	0.23%	0.1%	0.1%	0.08%	0.09%	1.15%	8.44%
Net Income	-164.44M	-271.39M	-289.4M	-245.19M	-235.26M	-281.58M	-167.87M	-215.97M	-61.29M	226.45M
Depreciation & Amortization	647K	1.83M	2.71M	3M	2.77M	2.93M	3.34M	2.03M	5.55M	15.88M
Stock-Based Compensation	40.19M	55.27M	75.53M	81.56M	82.27M	84.42M	63.62M	68.2M	66.42M	67.05M
Deferred Taxes	-247K	-596K	0	0	0	2.75M	0	0	0	0
Other Non-Cash Items	-2.06M	94K	-287K	1.35M	-4.61M	44.28M	75K	-6.28M	-12.12M	-155.82M
Working Capital Changes	4.11M	4.39M	-6.41M	-8.2M	3.71M	11.04M	-24.82M	37.99M	18.13M	4.16M
Change in Receivables	-674K	-5.9M	-11.44M	-8.75M	-9.69M	-12.47M	-16.12M	2.26M	-39.27M	-2.35M
Change in Inventory	0	-3.31M	-1.01M	1.93M	-1.74M	-3.32M	-4.21M	2.42M	-28.81M	-49.55M
Change in Payables	-344K	2.24M	4.87M	-5.62M	4.05M	1.27M	-1.62M	5.87M	4.8M	-1.35M
Cash from Investing+	147.57M	-261.92M	92.47M	-71.49M	-165.84M	192.51M	-71.1M	73.24M	32M	-30.54M
Capital Expenditures	-2.14M	-9.51M	-812K	-2.15M	-1.13M	-7.59M	-1.12M	0	-40.05M	-523K
CapEx % of Revenue	35.1%	0.55%	0.01%	0.01%	0%	0.02%	0%	-	0.06%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.06M	-8M	93.28M	44K	-164.71M	200.1M	-69.98M	0	32.05M	146.51M
Cash from Financing+	14.5M	533.81M	31.19M	306.65M	371.85M	81M	18.16M	8.2M	25.13M	6.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-45K	14.92M	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-123.94M	-219.91M	-218.67M	-169.62M	-152.26M	-143.75M	-126.78M	-114.03M	-23.35M	157.2M
FCF Margin %	-2031.74%	-12.69%	-1.75%	-0.76%	-0.45%	-0.33%	-0.26%	-0.22%	-0.03%	0.16%
FCF Growth %	-0.86%	-0.77%	0.01%	0.22%	0.1%	0.06%	0.12%	0.1%	0.8%	7.73%
FCF per Share	-1.23	-1.90	-1.78	-1.34	-1.03	-0.91	-0.79	-0.71	-0.14	0.94
FCF Conversion (FCF/Net Income)	0.74x	0.78x	0.75x	0.68x	0.64x	0.48x	0.75x	0.53x	-0.27x	0.70x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	-415K	365K	1.37M	1.26M	1.6M	1.11M	1.04M	2.19M	5.85M	19.52M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-64.58%	-75.58%	-67.8%	-60.22%	-39.93%	-42.47%	-28.75%	-45.89%	-14.73%	38.89%
Return on Invested Capital (ROIC)	-71.52%	-90.45%	-70.67%	-60.83%	-42.82%	-49.42%	-31.62%	-41.64%	-16.99%	45.22%
Gross Margin	-125095.08%	74.58%	89.54%	91.81%	94.22%	95.35%	96.05%	98.03%	93.7%	91.46%
Net Margin	-269578.69%	-1565.94%	-231.71%	-109.56%	-69.38%	-63.74%	-34.67%	-41.76%	-8.44%	23.64%
Debt / Equity	-	-	-	-	0.01x	0.08x	0.12x	0.15x	0.13x	0.07x
FCF Conversion	0.74x	0.78x	0.75x	0.68x	0.64x	0.48x	0.75x	0.53x	-0.27x	0.70x
Revenue Growth	-49.17%	28311.48%	620.68%	79.19%	51.5%	30.28%	9.6%	6.83%	40.45%	31.85%

Revenue by Segment

	2018
Product	223.81M
Product Growth	-

Frequently Asked Questions

Valuation & Price

ACADIA Pharmaceuticals Inc. (ACAD) has a price-to-earnings (P/E) ratio of 19.8x. This is roughly in line with market averages.

Growth & Financials

ACADIA Pharmaceuticals Inc. (ACAD) reported $1.05B in revenue for fiscal year 2024. This represents a 50559% increase from $2.1M in 2011.

ACADIA Pharmaceuticals Inc. (ACAD) grew revenue by 31.8% over the past year. This is strong growth.

Yes, ACADIA Pharmaceuticals Inc. (ACAD) is profitable, generating $261.2M in net income for fiscal year 2024 (23.6% net margin).

Dividend & Returns

ACADIA Pharmaceuticals Inc. (ACAD) has a return on equity (ROE) of 38.9%. This is excellent, indicating efficient use of shareholder capital.

ACADIA Pharmaceuticals Inc. (ACAD) generated $197.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

ACADIA Pharmaceuticals Inc. (ACAD) 10-Year Financial Performance & Capital Metrics

ACAD • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $958M +31.8%
EBITDA $247M +463.7%
Net Income $226M +469.5%
EPS (Diluted) 1.36 +467.6%
Gross Margin 91.46% -2.4%
EBITDA Margin 25.75% +375.8%
Operating Margin 24.1% +338.5%
Net Margin 23.64% +380.2%
ROE 38.89% +364.0%
ROIC 45.22% +366.2%
Debt/Equity 0.07 -46.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 16.4% free cash flow margin
✓Strong 5Y sales CAGR of 23.1%
✓Trading near 52-week high

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y145.59%

5Y23.08%

3Y25.54%

TTM12.69%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM103.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM98.72%

ROCE

10Y Avg-40.06%

5Y Avg-17.89%

3Y Avg-7.14%

Latest35.85%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	61K	17.33M	124.9M	223.81M	339.08M	441.75M	484.14M	517.24M	726.44M	957.8M
Revenue Growth %	-0.49%	283.11%	6.21%	0.79%	0.52%	0.3%	0.1%	0.07%	0.4%	0.32%
Cost of Goods Sold+	76.37M	4.41M	13.06M	18.33M	19.6M	20.55M	19.14M	10.17M	45.73M	81.84M
COGS % of Revenue	1251.95%	0.25%	0.1%	0.08%	0.06%	0.05%	0.04%	0.02%	0.06%	0.09%
Gross Profit+	-76.31M	12.93M	111.84M	205.48M	319.48M	421.2M	465M	507.07M	680.71M	875.96M
Gross Margin %	-1250.95%	0.75%	0.9%	0.92%	0.94%	0.95%	0.96%	0.98%	0.94%	0.91%
Gross Profit Growth %	-0.26%	1.17%	7.65%	0.84%	0.55%	0.32%	0.1%	0.09%	0.34%	0.29%
Operating Expenses+	164.67M	285.74M	404.25M	452.92M	566.02M	707.79M	635.44M	730.66M	754.09M	645.16M
OpEx % of Revenue	2699.56%	16.49%	3.24%	2.02%	1.67%	1.6%	1.31%	1.41%	1.04%	0.67%
Selling, General & Admin	90.8M	186.46M	255.06M	265.76M	325.64M	388.66M	396.03M	369.09M	402.47M	488.43M
SG&A % of Revenue	1488.59%	10.76%	2.04%	1.19%	0.96%	0.88%	0.82%	0.71%	0.55%	0.51%
Research & Development	73.87M	99.28M	149.19M	187.16M	240.38M	319.13M	239.41M	361.57M	351.62M	303.25M
R&D % of Revenue	1210.97%	5.73%	1.19%	0.84%	0.71%	0.72%	0.49%	0.7%	0.48%	0.32%
Other Operating Expenses	2.5M	1.33M	3.98M	-1.84M	0	0	0	0	0	-146.51M
Operating Income+	-164.61M	-272.81M	-292.41M	-247.44M	-246.54M	-286.59M	-170.44M	-223.6M	-73.38M	230.79M
Operating Margin %	-2698.56%	-15.74%	-2.34%	-1.11%	-0.73%	-0.65%	-0.35%	-0.43%	-0.1%	0.24%
Operating Income Growth %	-0.77%	-0.66%	-0.07%	0.15%	0%	-0.16%	0.41%	-0.31%	0.67%	4.15%
EBITDA+	-163.97M	-270.99M	-289.7M	-244.44M	-243.78M	-283.65M	-167.09M	-221.57M	-67.83M	246.68M
EBITDA Margin %	-2687.95%	-15.64%	-2.32%	-1.09%	-0.72%	-0.64%	-0.35%	-0.43%	-0.09%	0.26%
EBITDA Growth %	-0.76%	-0.65%	-0.07%	0.16%	0%	-0.16%	0.41%	-0.33%	0.69%	4.64%
D&A (Non-Cash Add-back)	647K	1.83M	2.71M	3M	2.77M	2.93M	3.34M	2.03M	5.55M	15.88M
EBIT	-164.61M	-272.81M	-292.41M	-247.44M	-246.54M	-286.59M	-170.44M	-223.6M	-73.38M	84.28M
Net Interest Income+	499K	2.76M	4.13M	5.35M	11.16M	6.61M	591K	6.61M	17.23M	25.46M
Interest Income	499K	2.76M	4.13M	5.35M	11.16M	6.61M	591K	6.61M	17.23M	25.46M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	499K	2.76M	4.13M	3.51M	12.16M	5.61M	2.92M	10.15M	22.34M	27.28M
Pretax Income+	-164.11M	-270.05M	-288.28M	-243.94M	-234.38M	-280.97M	-167.52M	-213.44M	-51.04M	258.07M
Pretax Margin %	-2690.38%	-15.58%	-2.31%	-1.09%	-0.69%	-0.64%	-0.35%	-0.41%	-0.07%	0.27%
Income Tax+	330K	1.34M	1.12M	1.26M	876K	611K	351K	2.53M	10.25M	31.62M
Effective Tax Rate %	1%	1%	1%	1.01%	1%	1%	1%	1.01%	1.2%	0.88%
Net Income+	-164.44M	-271.39M	-289.4M	-245.19M	-235.26M	-281.58M	-167.87M	-215.97M	-61.29M	226.45M
Net Margin %	-2695.79%	-15.66%	-2.32%	-1.1%	-0.69%	-0.64%	-0.35%	-0.42%	-0.08%	0.24%
Net Income Growth %	-0.78%	-0.65%	-0.07%	0.15%	0.04%	-0.2%	0.4%	-0.29%	0.72%	4.69%
Net Income (Continuing)	-164.44M	-271.39M	-289.4M	-245.19M	-235.26M	-281.58M	-167.87M	-215.97M	-61.29M	226.45M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.63	-2.34	-2.36	-1.94	-1.60	-1.79	-1.05	-1.34	-0.37	1.36
EPS Growth %	-0.72%	-0.44%	-0.01%	0.18%	0.18%	-0.12%	0.41%	-0.28%	0.72%	4.68%
EPS (Basic)	-1.63	-2.34	-2.36	-1.94	-1.60	-1.79	-1.05	-1.34	-0.37	1.37
Diluted Shares Outstanding	100.63M	115.86M	122.6M	126.58M	147.2M	157.33M	160.49M	161.68M	163.82M	166.36M
Basic Shares Outstanding	100.63M	115.86M	122.6M	126.58M	147.2M	157.33M	160.49M	161.68M	163.82M	165.72M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	218.99M	547.9M	373.48M	526.11M	760.25M	717.62M	617.82M	507.94M	616.13M	938.32M
Cash & Short-Term Investments	215.13M	529.04M	341.34M	473.52M	697.43M	631.96M	520.71M	416.82M	438.87M	755.99M
Cash Only	102.14M	163.62M	69.42M	134.76M	189.68M	326.03M	147.44M	114.85M	188.66M	319.59M
Short-Term Investments	112.99M	365.42M	271.92M	338.76M	507.75M	305.93M	373.27M	301.98M	250.21M	436.4M
Accounts Receivable	1.64M	7.14M	18.43M	27.79M	37.87M	50.28M	65.34M	63.08M	102.35M	104.69M
Days Sales Outstanding	9.8K	150.37	53.86	45.32	40.77	41.55	49.26	44.51	51.43	39.9
Inventory	0	4.17M	5.25M	4.07M	6.34M	9.68M	7.88M	6.64M	35.82M	21.95M
Days Inventory Outstanding	-	345.86	146.67	81.04	118.1	171.97	150.28	238.26	285.89	97.89
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	2.91M	13.26M	11.03M	14.1M	22.93M	65M	82.3M	79.88M	132.83M	249.44M
Property, Plant & Equipment	2.2M	3.08M	2.66M	3.31M	12.7M	56.44M	66.31M	61.59M	56.47M	50.79M
Fixed Asset Turnover	0.03x	5.63x	46.92x	67.64x	26.69x	7.83x	7.30x	8.40x	12.86x	18.86x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	7.01M	5.54M	4.06M	2.58M	1.11M	0	0	65.49M	119.78M
Long-Term Investments	375K	2.38M	2.48M	4.83M	7.09M	7.07M	0	12.97M	5.77M	0
Other Non-Current Assets	329K	3.16M	2.83M	6.72M	557K	378K	15.98M	5.31M	5.1M	78.87M
Total Assets+	221.9M	561.15M	384.51M	540.2M	783.18M	782.62M	700.12M	587.81M	748.96M	1.19B
Asset Turnover	0.00x	0.03x	0.32x	0.41x	0.43x	0.56x	0.69x	0.88x	0.97x	0.81x
Asset Growth %	-0.32%	1.53%	-0.31%	0.4%	0.45%	-0%	-0.11%	-0.16%	0.27%	0.59%
Total Current Liabilities+	21.9M	42.59M	49.03M	59.56M	74.83M	105.97M	96.07M	125.63M	254.25M	394.87M
Accounts Payable	1.67M	3.91M	8.79M	3.17M	7.22M	8.49M	6.88M	12.75M	17.54M	16.19M
Days Payables Outstanding	7.99	324.08	245.55	63.06	134.51	150.85	131.12	457.63	140.02	72.21
Short-Term Debt	0	0	0	0	3.43M	5.09M	0	0	9.4M	0
Deferred Revenue (Current)	0	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	14.51M	21.65M	21.39M	33.52M	31.76M	52.46M	25.9M	49.51M	92.31M	36.55M
Current Ratio	10.00x	12.87x	7.62x	8.83x	10.16x	6.77x	6.43x	4.04x	2.42x	2.38x
Quick Ratio	10.00x	12.77x	7.51x	8.76x	10.08x	6.68x	6.35x	3.99x	2.28x	2.32x
Cash Conversion Cycle	-	172.16	-45.02	63.3	24.36	62.66	68.43	-174.86	197.3	65.57
Total Non-Current Liabilities+	232K	157K	191K	1.56M	9.22M	49.64M	63.16M	61.77M	62.95M	60.09M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	6.36M	44.46M	56.13M	52.7M	47.8M	42.04M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	232K	157K	191K	1.56M	2.86M	5.18M	7.03M	9.07M	15.15M	18.06M
Total Liabilities	22.13M	42.74M	49.22M	61.12M	84.05M	155.61M	159.23M	187.4M	317.2M	454.96M
Total Debt+	0	0	0	0	9.79M	49.55M	64.43M	62M	57.2M	51.99M
Net Debt	-102.14M	-163.62M	-69.42M	-134.76M	-179.88M	-276.48M	-83M	-52.85M	-131.45M	-267.59M
Debt / Equity	-	-	-	-	0.01x	0.08x	0.12x	0.15x	0.13x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.21x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-1.08x
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	199.76M	518.41M	335.29M	479.08M	699.13M	627.01M	540.89M	400.41M	431.75M	732.79M
Equity Growth %	-0.35%	1.6%	-0.35%	0.43%	0.46%	-0.1%	-0.14%	-0.26%	0.08%	0.7%
Book Value per Share	1.99	4.47	2.73	3.78	4.75	3.99	3.37	2.48	2.64	4.40
Total Shareholders' Equity	199.76M	518.41M	335.29M	479.08M	699.13M	627.01M	540.89M	400.41M	431.75M	732.79M
Common Stock	10K	12K	12K	14K	15K	16K	16K	16K	16K	16K
Retained Earnings	-662.59M	-933.98M	-1.22B	-1.47B	-1.7B	-1.99B	-2.15B	-2.37B	-2.43B	-2.2B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	11K	106K	-399K	-372K	297K	36K	-192K	-975K	24K	292K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-121.8M	-210.41M	-217.86M	-167.47M	-151.13M	-136.17M	-125.66M	-114.03M	16.7M	157.72M
Operating CF Margin %	-1996.64%	-12.14%	-1.74%	-0.75%	-0.45%	-0.31%	-0.26%	-0.22%	0.02%	0.16%
Operating CF Growth %	-0.83%	-0.73%	-0.04%	0.23%	0.1%	0.1%	0.08%	0.09%	1.15%	8.44%
Net Income	-164.44M	-271.39M	-289.4M	-245.19M	-235.26M	-281.58M	-167.87M	-215.97M	-61.29M	226.45M
Depreciation & Amortization	647K	1.83M	2.71M	3M	2.77M	2.93M	3.34M	2.03M	5.55M	15.88M
Stock-Based Compensation	40.19M	55.27M	75.53M	81.56M	82.27M	84.42M	63.62M	68.2M	66.42M	67.05M
Deferred Taxes	-247K	-596K	0	0	0	2.75M	0	0	0	0
Other Non-Cash Items	-2.06M	94K	-287K	1.35M	-4.61M	44.28M	75K	-6.28M	-12.12M	-155.82M
Working Capital Changes	4.11M	4.39M	-6.41M	-8.2M	3.71M	11.04M	-24.82M	37.99M	18.13M	4.16M
Change in Receivables	-674K	-5.9M	-11.44M	-8.75M	-9.69M	-12.47M	-16.12M	2.26M	-39.27M	-2.35M
Change in Inventory	0	-3.31M	-1.01M	1.93M	-1.74M	-3.32M	-4.21M	2.42M	-28.81M	-49.55M
Change in Payables	-344K	2.24M	4.87M	-5.62M	4.05M	1.27M	-1.62M	5.87M	4.8M	-1.35M
Cash from Investing+	147.57M	-261.92M	92.47M	-71.49M	-165.84M	192.51M	-71.1M	73.24M	32M	-30.54M
Capital Expenditures	-2.14M	-9.51M	-812K	-2.15M	-1.13M	-7.59M	-1.12M	0	-40.05M	-523K
CapEx % of Revenue	35.1%	0.55%	0.01%	0.01%	0%	0.02%	0%	-	0.06%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.06M	-8M	93.28M	44K	-164.71M	200.1M	-69.98M	0	32.05M	146.51M
Cash from Financing+	14.5M	533.81M	31.19M	306.65M	371.85M	81M	18.16M	8.2M	25.13M	6.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-45K	14.92M	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-123.94M	-219.91M	-218.67M	-169.62M	-152.26M	-143.75M	-126.78M	-114.03M	-23.35M	157.2M
FCF Margin %	-2031.74%	-12.69%	-1.75%	-0.76%	-0.45%	-0.33%	-0.26%	-0.22%	-0.03%	0.16%
FCF Growth %	-0.86%	-0.77%	0.01%	0.22%	0.1%	0.06%	0.12%	0.1%	0.8%	7.73%
FCF per Share	-1.23	-1.90	-1.78	-1.34	-1.03	-0.91	-0.79	-0.71	-0.14	0.94
FCF Conversion (FCF/Net Income)	0.74x	0.78x	0.75x	0.68x	0.64x	0.48x	0.75x	0.53x	-0.27x	0.70x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	-415K	365K	1.37M	1.26M	1.6M	1.11M	1.04M	2.19M	5.85M	19.52M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-64.58%	-75.58%	-67.8%	-60.22%	-39.93%	-42.47%	-28.75%	-45.89%	-14.73%	38.89%
Return on Invested Capital (ROIC)	-71.52%	-90.45%	-70.67%	-60.83%	-42.82%	-49.42%	-31.62%	-41.64%	-16.99%	45.22%
Gross Margin	-125095.08%	74.58%	89.54%	91.81%	94.22%	95.35%	96.05%	98.03%	93.7%	91.46%
Net Margin	-269578.69%	-1565.94%	-231.71%	-109.56%	-69.38%	-63.74%	-34.67%	-41.76%	-8.44%	23.64%
Debt / Equity	-	-	-	-	0.01x	0.08x	0.12x	0.15x	0.13x	0.07x
FCF Conversion	0.74x	0.78x	0.75x	0.68x	0.64x	0.48x	0.75x	0.53x	-0.27x	0.70x
Revenue Growth	-49.17%	28311.48%	620.68%	79.19%	51.5%	30.28%	9.6%	6.83%	40.45%	31.85%

Revenue by Segment

	2018
Product	223.81M
Product Growth	-

Frequently Asked Questions

Valuation & Price

ACADIA Pharmaceuticals Inc. (ACAD) has a price-to-earnings (P/E) ratio of 19.8x. This is roughly in line with market averages.

Growth & Financials

ACADIA Pharmaceuticals Inc. (ACAD) reported $1.05B in revenue for fiscal year 2024. This represents a 50559% increase from $2.1M in 2011.

ACADIA Pharmaceuticals Inc. (ACAD) grew revenue by 31.8% over the past year. This is strong growth.

Yes, ACADIA Pharmaceuticals Inc. (ACAD) is profitable, generating $261.2M in net income for fiscal year 2024 (23.6% net margin).

Dividend & Returns

ACADIA Pharmaceuticals Inc. (ACAD) has a return on equity (ROE) of 38.9%. This is excellent, indicating efficient use of shareholder capital.

ACADIA Pharmaceuticals Inc. (ACAD) generated $197.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.